Northwire Canada EditionSaturday, October 17, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4181.10 +0.3% SILVER 57.30 +0.3% COPPER 6.57 +0.3% OIL 99.02 +1.1% PALLADIUM 1118.60 −0.9% GBU 0.095 +0.0% ATY 0.225 +4.7% GRDM 0.215 +0.0% PPM 0.300 +0.0% GZD 0.040 −11.1% CAN 0.060 +0.0% BGF 0.025 +0.0% MSV 0.570 +0.0% CCMM 0.485 +0.0% MON 0.385 −6.1% OMI 0.245 −2.0% BUFF 0.800 +2.6% FEO 0.630 −3.1% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0% GOLD 4181.10 +0.3% SILVER 57.30 +0.3% COPPER 6.57 +0.3% OIL 99.02 +1.1% PALLADIUM 1118.60 −0.9% GBU 0.095 +0.0% ATY 0.225 +4.7% GRDM 0.215 +0.0% PPM 0.300 +0.0% GZD 0.040 −11.1% CAN 0.060 +0.0% BGF 0.025 +0.0% MSV 0.570 +0.0% CCMM 0.485 +0.0% MON 0.385 −6.1% OMI 0.245 −2.0% BUFF 0.800 +2.6% FEO 0.630 −3.1% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0%
M&A / Property

Tempramed forms media partnership with Dr. Phil, Envoy

By The Northwire Desk — AI Analysis Feb 02, 2026 · 12:41 VIVI · 1.00 Tempramed Technologies Ltd
VIVI · Price

Executive Summary

  • Tempramed Technologies Ltd. has entered into a strategic media partnership with Dr. Phil and Envoy Media to accelerate market adoption and brand authority in the United States.
  • The agreement includes exclusive title sponsorship of a 44-minute Dr. Phil television special focused on prescription medication safety, scheduled to air in May 2026.
  • The partnership provides Tempramed with access to an audience of over 19 million monthly viewers and full content usage rights for long-term monetization across digital, B2B, and international channels.

Key Details

  • Partnership Structure: Strategic media partnership between Tempramed Technologies Ltd. and Dr. Phil/Envoy Media.
  • Sponsorship Role: Tempramed serves as the exclusive title sponsor of a full-length, 44-minute Dr. Phil-hosted television special.
  • Content Focus: The special addresses common and dangerous mistakes regarding prescription medication temperature exposure, positioning Tempramed as the featured solution with no competing brands.
  • Air Date: The special is scheduled to air as a Dr. Phil Envoy TV special in May 2026.
  • Audience Reach: Access to an audience of over 19 million monthly viewers across broadcast and digital platforms, with a social following exceeding 25 million users.
  • Distribution Channels: Multiplatform distribution including broadcast TV, podcasts, YouTube, and social media.
  • Content Rights: Tempramed receives full content usage rights to repurpose the special for paid media, digital acquisition, enterprise sales, payer engagement, and international expansion.
  • Campaign Strategy: The initiative supports Tempramed's transition from awareness building to scaled demand generation and enterprise engagement.
  • Product Integration: The segment includes an on-air interview with a Tempramed spokesperson, integrated calls to action, and persistent on-screen branding.

Notable Quotes

  • "Dr. Phil brings unmatched credibility and reach to conversations that matter deeply to patients and families... This partnership allows us to educate millions of people about a largely overlooked risk in medication use -- temperature exposure -- while positioning Tempramed as the clear, trusted solution for medication storage and management. For our investors, this is about accelerating awareness, demand and enterprise engagement at national scale." — Ron Nagar, Chief Executive Officer of Tempramed
Read the original news release →

More from Tempramed Technologies Ltd

Jun 30, 2026 · 03:06

TempraMed Expands Strategic Partnership with McKesson Medical-Surgical to Accelerate North American Growth and Launch Full Portfolio Across B2B Channels

M&A / Property Jun 26, 2026 · 16:11

Pioneering passive thermal protection for temperature-sensitive injectables amid aggressive global distribution expansion.

M&A / Property Jun 04, 2026 · 07:01

TempraMed Signs Agreement for Exclusive Distribution Partnership in Brazil, One of the Largest Diabetes and Biologics Markets Globally

Other May 22, 2026 · 11:58

TempraMed Technologies Ltd.

Other May 14, 2026 · 03:01

Indian patent adds IP depth but revenue-sharing financing signals cash crunch

Financings Apr 07, 2026 · 07:01

Brazilian patent bolsters TempraMed’s IP moat ahead of VIVI Box launch.

M&A / Property